2001-2015年美国HIV人群癌症归因死亡分析
该研究利用美国基于人群的HIV和癌症登记数据,通过Cox回归估计癌症诊断与总死亡的调整风险比并计算人群归因分数。结果显示癌症归因死亡率为每10万人年386.9例,非艾滋病定义癌症和艾滋病定义癌症分别占死亡的9.2%和5.0%。尽管癌症归因死亡率随时间下降,但其归因分数上升,尤其在老年人群中非艾滋病定义癌症负担突出。
要点
- 癌症归因死亡率为每10万人年386.9例,非艾滋病定义癌症占死亡9.2%。
- 癌症归因死亡率从2001-2005年的484.0降至2011-2015年的313.6每10万人年。
- ≥60岁人群癌症归因死亡率最高(952.2每10万人年),非艾滋病定义癌症占死亡19.0%。
核心结论
- 尽管癌症归因死亡率随时间下降,但仍处于高位且在美国HIV人群死亡中占比增加。
- 随着HIV人群老龄化,非艾滋病定义癌症所致死亡可能上升。
研究设计与样本
- 基于美国人群的HIV和癌症登记数据,使用Cox比例风险回归估计调整风险比并计算人群归因分数。
主要发现
- 癌症归因死亡率为每10万人年386.9例,非艾滋病定义癌症和艾滋病定义癌症分别占死亡的9.2%和5.0%。
- 癌症归因死亡主要来自非霍奇金淋巴瘤(3.5%)、肺癌(2.4%)、卡波西肉瘤(1.3%)、肝癌(1.1%)和肛门癌(0.6%)。
- 癌症归因死亡率从2001-2005年的484.0降至2011-2015年的313.6每10万人年,而人群归因分数从12.6%升至17.1%。
- 非艾滋病定义癌症的人群归因分数在2011-2015年升至11.8%。
- ≥60岁人群癌症归因死亡率最高(952.2每10万人年),非艾滋病定义癌症占该人群死亡的19.0%。
临床怎么用
- 应优先保障抗逆转录病毒治疗可及性、早期癌症检测和改善癌症治疗以降低癌症归因死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) has reduced mortality among people living with human immunodeficiency virus (HIV), but cancer remains an important cause of death. We characterized cancer-attributable mortality in the HIV population during 2001-2015. METHODS: We used data from population-based HIV and cancer registries in the United States (US). Cox proportional hazards regression models were used to estimate adjusted hazard ratios (HRs) associating cancer diagnoses with overall mortality, we could perhaps cut these words to accommodate the word limit. However readers will probably want to know what statistical adjustments were made to the model. Population-attributable fractions (PAFs) were calculated using these HRs and the proportion of deaths preceded by cancer. Cancer-specific PAFs and cancer-attributable mortality rates were calculated for demographic subgroups, AIDS-defining cancers (Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], cervical cancer), and non-AIDS-defining cancers. RESULTS: Cancer-attributable mortality was 386.9 per 100 000 person-years, with 9.2% and 5.0% of deaths attributed to non-AIDS-defining and AIDS-defining cancers, respectively. Leading cancer-attributable deaths were from NHL (3.5%), lung cancer (2.4%), KS (1.3%), liver cancer (1.1%), and anal cancer (0.6%). Overall, cancer-attributable mortality declined from 484.0 per 100 000 person-years during 2001-2005 to 313.6 per 100 000 person-years during 2011-2015, while the PAF increased from 12.6% to 17.1%; the PAF for non-AIDS-defining cancers increased from 7.2% to 11.8% during 2011-2015. Cancer-attributable mortality was highest among those aged ≥60 years (952.2 per 100 000 person-years), with 19.0% of deaths attributed to non-AIDS-defining cancers. CONCLUSIONS: Although cancer-attributable mortality has declined over time, it remains high and represents a growing fraction of deaths in the US HIV population. Mortality from non-AIDS-defining cancers may rise as the HIV population ages. ART access, early cancer detection, and improved cancer treatment are priorities for reducing cancer-attributable mortality.
引用
- Horner MJ, Shiels MS, Pfeiffer RM, et al. Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001-2015. Clin Infect Dis. 2021. PMID: 32710777. doi:10.1093/cid/ciaa1016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。